DeepMed Research

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Giredestrant

Generic Name: Giredestrant

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Phase 3

Recruiting

Posted: 2023/10/04

Sponsor:Hoffmann-La Roche

A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer

Phase 2

Recruiting

Posted: 2023/06/09

Sponsor:ETOP IBCSG Partners ...

A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population

Phase 2

Active, not recruiting

Posted: 2023/02/01

Sponsor:

MedSIR

Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10%

Phase 2

Completed

Posted: 2022/12/21

Sponsor:

MedSIR

A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer

Phase 2

Active, not recruiting

Posted: 2022/12/02

Sponsor:Hoffmann-La Roche

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Samuraciclib Shows Promise in HR+ Breast Cancer Patients Without TP53 Mutations or Liver Metastases

14 days ago

Carrick Therapeutics' CDK7 inhibitor samuraciclib demonstrated significantly extended progression-free survival in HR+ advanced breast cancer patients without TP53 mutations or liver metastases in two independent Phase 2 trials.

Sanofi Halts Amcenestrant Development After Disappointing First-Line Breast Cancer Trial

4 months ago

Sanofi discontinues the development of amcenestrant, an oral selective estrogen receptor degrader (SERD), after it failed in the AMEERA-5 phase 3 trial.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy